Brentuximab vedotin

References

• Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73:1349 - 60; http://dx.doi.org/10.1016/0092-8674(93)90361-S; PMID: 8391931
   PubMed Web of Science ®Google Scholar
• Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17:1535 - 42; PMID: 9032281
   PubMed Web of Science ®Google Scholar
• Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A 1996; 93:14053 - 8; http://dx.doi.org/10.1073/pnas.93.24.14053; PMID: 8943059
   PubMed Web of Science ®Google Scholar
• Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol 2002; 169:2451 - 9; PMID: 12193714
   PubMed Web of Science ®Google Scholar
• Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 156:1723 - 31; http://dx.doi.org/10.1016/S0002-9440(10)65043-2; PMID: 10793083
   PubMed Web of Science ®Google Scholar
• Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151:387 - 96; http://dx.doi.org/10.1111/j.1365-2141.2010.08342.x; PMID: 20880107
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75:282 - 4; http://dx.doi.org/10.1111/j.1365-2141.1990.tb02664.x; PMID: 2164839
   PubMed Web of Science ®Google Scholar
• Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12:793 - 7; PMID: 8151321
   PubMed Web of Science ®Google Scholar
• Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, et al. Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice. Cell 1996; 84:551 - 62; http://dx.doi.org/10.1016/S0092-8674(00)81031-4; PMID: 8598042
   PubMed Web of Science ®Google Scholar
• DeYoung AL, Duramad O, Winoto A. The TNF receptor family member CD30 is not essential for negative selection. J Immunol 2000; 165:6170 - 3; PMID: 11086050
   PubMed Web of Science ®Google Scholar
• Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, et al. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011; 244:134 - 48; http://dx.doi.org/10.1111/j.1600-065X.2011.01057.x; PMID: 22017436
   PubMed Web of Science ®Google Scholar
• Tang C, Yamada H, Shibata K, Muta H, Wajjwalku W, Podack ER, et al. A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol 2008; 181:6316 - 27; PMID: 18941223
   PubMed Web of Science ®Google Scholar
• Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002; 196:829 - 39; http://dx.doi.org/10.1084/jem.20020319; PMID: 12235215
   PubMed Web of Science ®Google Scholar
• Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995; 57:726 - 30; PMID: 7759952
   PubMed Web of Science ®Google Scholar
• Bengtsson A. The role of CD30 in atopic disease. Allergy 2001; 56:593 - 603; http://dx.doi.org/10.1034/j.1398-9995.2001.00137.x; PMID: 11421916
   PubMed Web of Science ®Google Scholar
• Gaspal F, Withers D, Saini M, Bekiaris V, McConnell FM, White A, et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice. J Exp Med 2011; 208:1579 - 84; http://dx.doi.org/10.1084/jem.20101484; PMID: 21788408
   PubMed Web of Science ®Google Scholar
• Chakrabarty S, Nagata M, Yasuda H, Wen L, Nakayama M, Chowdhury SA, et al. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol 2003; 133:318 - 25; http://dx.doi.org/10.1046/j.1365-2249.2003.02223.x; PMID: 12930356
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006; 118:143 - 52; http://dx.doi.org/10.1111/j.1365-2567.2006.02354.x; PMID: 16771849
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83:2045 - 56; PMID: 8161776
   PubMed Web of Science ®Google Scholar
• Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012; 119:990 - 6; http://dx.doi.org/10.1182/blood-2010-08-302604; PMID: 22147892
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111:2977 - 83; http://dx.doi.org/10.1182/blood-2007-10-115493; PMID: 18096762
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119:692 - 5; http://dx.doi.org/10.1182/blood-2011-09-378414; PMID: 22117038
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339:1506 - 14; http://dx.doi.org/10.1056/NEJM199811193392104; PMID: 9819449
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625 - 33; http://dx.doi.org/10.1093/annonc/mdi119; PMID: 15737986
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006; 12:1065 - 72; http://dx.doi.org/10.1016/j.bbmt.2006.06.006; PMID: 17084370
   PubMed Web of Science ®Google Scholar
• Martinez C, Canals C, Alessandrino E, Karakasis D, Leone G, Trneny M, et al. Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol 2010; 28:8060
   Google Scholar
• Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al, International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496 - 504; http://dx.doi.org/10.1182/blood-2008-01-134270; PMID: 18385450
   PubMed Web of Science ®Google Scholar
• Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al, British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451 - 85; http://dx.doi.org/10.1111/j.1365-2141.2011.08651.x; PMID: 21480860
   PubMed Web of Science ®Google Scholar
• Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024 - 35; http://dx.doi.org/10.1182/blood-2011-05-351346; PMID: 21841159
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778 - 84; http://dx.doi.org/10.1038/nbt832; PMID: 12778055
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16:888 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-09-2069; PMID: 20086002
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102:1458 - 65; http://dx.doi.org/10.1182/blood-2003-01-0039; PMID: 12714494
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008; 142:69 - 73; http://dx.doi.org/10.1111/j.1365-2141.2008.07146.x; PMID: 18477046
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812 - 21; http://dx.doi.org/10.1056/NEJMoa1002965; PMID: 21047225
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18:248 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-11-1425; PMID: 22080439
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764 - 9; http://dx.doi.org/10.1200/JCO.2006.07.8972; PMID: 17515574
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146:171 - 9; http://dx.doi.org/10.1111/j.1365-2141.2009.07740.x; PMID: 19466965
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008; 111:1848 - 54; http://dx.doi.org/10.1182/blood-2007-07-099317; PMID: 18079362
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011; 29:8031
   Google Scholar
• Chen RW, Forman SJ, Palmer J, Tsai N-C, Popplewell L, Delioukina ML, et al. Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2011; 118: 664.
   Google Scholar
• Illidge T, Bouabdallah R, Chen RW, Gopal AK, Moskowitz CH, Ramchandren R, et al. Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. ASH Annual Meeting Abstracts 2011; 118: 3091.
   Google Scholar
• Younes A, Connors JM, Park SI, Hunder NNH, Ansell SM. Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2011; 118: 955.
   Google Scholar
• Advani RH, Shustov AR, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. ASH Annual Meeting Abstracts 2011; 118: 443.
   Google Scholar
• Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma 2012; 53:506 - 7; http://dx.doi.org/10.3109/10428194.2011.614706; PMID: 21867368
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Grove LE, Kennedy D, Sievers EL, Forero A. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. J Clin Oncol 2010; 28:8062
   Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009; 15:6217 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-09-0162; PMID: 19789316
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85:320 - 4; PMID: 20229590
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119 - 25; http://dx.doi.org/10.1182/blood-2011-07-362475; PMID: 21937701
   PubMed Web of Science ®Google Scholar
• Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin’s lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010:93 - 100; http://dx.doi.org/10.1182/asheducation-2010.1.93; PMID: 21239777
   PubMed Web of Science ®Google Scholar
• Merkel O, Hamacher F, Sifft E, Kenner L, Greil R, European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011; 10:1127 - 36; http://dx.doi.org/10.1158/1535-7163.MCT-11-0042; PMID: 21712478
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117:5827 - 34; http://dx.doi.org/10.1182/blood-2010-10-312603; PMID: 21355097
   PubMed Web of Science ®Google Scholar
• d’Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010; 150:565 - 73; http://dx.doi.org/10.1111/j.1365-2141.2010.08298.x; PMID: 20629661
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357 - 64; http://dx.doi.org/10.1200/JCO.2008.20.8470; PMID: 19652067
   PubMed Web of Science ®Google Scholar
• Lindén O. Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. N Engl J Med 2004; 351:1466 - 7; http://dx.doi.org/10.1056/NEJM200409303511424; PMID: 15459315
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Berryman RB, Advani RH, Bartlett NL, Chen RW, Fanale MA, et al. Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). ASH Annual Meeting Abstracts 2011; 118: 3711.
   Google Scholar
• Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, et al, Cancer and Leukemia Group B. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol 2010; 21:2246 - 54; http://dx.doi.org/10.1093/annonc/mdq211; PMID: 20423913
   PubMed Web of Science ®Google Scholar
• Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 2009; 15:3376 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-08-3222; PMID: 19401346
   PubMed Web of Science ®Google Scholar
• Blum KA, Smith M, Fung H, Zalevsky J, Combs D, Ramies DA, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol 2009; 27:8531
   Google Scholar